A role for advanced glycation end products in diminished bone healing in type 1 diabetes

Diabetes

Volumn 52, Issue 6, 2003, Pages 1502-1510

  Santana, Ronaldo B ^a   Xu, Lei ^a   Chase, Hermik Babakhanlou ^a   Amar, Salomon ^a,b   Graves, Dana T ^a,b   Trackman, Philip C ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERAL; BONE TISSUE; CELL CULTURE; CONTROLLED STUDY; CRANIOTOMY; DISEASE ASSOCIATION; FRACTURE HEALING; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3 CELLS; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CRANIOTOMY; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSURIA; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; INSULIN; KETONES; MICE; MICE, INBRED BALB C; OSTEOBLASTS; PROTEINURIA; RATS; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKULL; WOUND HEALING;

EID: 0038321284     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.6.1502     Document Type: Article

References (53)

1. 125I photon-absorption technique. Diabetes 26:1130-1135, 1977
2. Heath H 3rd, Lambert PW, Service FJ, Arnaud SB: Calcium homeostasis in diabetes mellitus. J Clin Endocrinol Metab 49:462-466, 1979
3. McNair P, Madsbad S, Christiansen C, Faber OK, Transbol I, Binder C: Osteopenia in insulin treated diabetes mellitus: its relation to age at onset, sex and duration of disease. Diabetologia 15:87-90, 1978
4. Levin ME, Boisseau VC, Avioli LV: Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 294:241-245, 1976
5. Santiago JV, McAlister WH, Ratzan SK, Bussman Y, Haymond MW, Shackelford G, Weldon VV: Decreased cortical thickness and osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab 45:845-848, 1977
6. Seino Y, Ishida H: Diabetic osteopenia: pathophysiology and clinical aspects. Diabetes Metab Rev 11:21-35, 1995
7. Levy J, Reid I, Halstad L, Gavin JR, Avioli LV: Abnormal cell calcium concentrations in cultured bone cells obtained from femurs of obese and noninsulin-dependent diabetic rats. Calcif Tissue Int 44:131-137, 1989
8. Cozen L: Does diabetes delay fracture healing? Clin Orthop 82:134-140, 1972
9. Bouillon R, Bex M, Van Herck E, Laureys J, Dooms L, Lesaffre E, Ravussin E: Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 80:1194-1202, 1995
10. Bouillon R: Diabetic bone disease: low turnover osteoporosis related to decreased IGF-I production. Verh K Acad Geneeskd Belg 54:365-391, 1992
11. Aubia J, Serrano LI, Marinoso L, Hojman L, Diez A, Lloveras J, Masramon J: Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study. Calcif Tissue Int 42:297-301, 1988
12. Rico H, Hernandez ER, Cabranes JA, Gomez-Castresana F: Suggestion of a deficient osteoblastic function in diabetes mellitus: the possible cause of osteopenia in diabetics. Calcif Tissue Int 45:71-73, 1989
13. Shore RM, Chesney RW, Mazess RB, Rose PG, Bargman GJ: Osteopenia in juvenile diabetes. Calcif Tissue Int 33:455-457, 1981
14. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM: Bone loss and bone turnover in diabetes. Diabetes 44:775-782, 1995
15. Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 4:437-451, 1988
16. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
17. Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J 6:2905-2914, 1992
18. Lalla E, Lamster IB, Feit M, Huang L, Schmidt AM: A murine model of accelerated periodontal disease in diabetes. J Periodontal Res 33:387-399, 1998
19. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM: Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 105:1117-1124, 2000
20. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749, 1999
21. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM: Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21:905-910, 2001
22. Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99-111, 2000
23. Baynes JW, Watkins NG, Fisher CI, Hull CJ, Patrick JS, Ahmed MU, Dunn JA, Thorpe SR: The Amadori product on protein: structure and reactions. Prog Clin Biol Res 304:43-67, 1989
24. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174:931-939, 1991
25. Vlassara H, Brownlee M, Cerami A: Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37:456-461, 1988
26. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
27. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
28. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D: RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 (Suppl. 3):S77-S80, 1996
29. Lalla E, Lamster IB, Schmidt AM: Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. Ann Periodontol 3:13-19, 1998
30. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF: The advanced glycation end product N epsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 21:1997-2002, 1998
31. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW: Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205-1210, 1991
32. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35:8075-8083, 1996
33. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: N epsilon(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872-10878, 1995
34. Schleicher ED, Wagner E, Nerlich AG: Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457-468, 1997
35. Like AA, Rossini AA: Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415-417, 1976
36. Marden LJ, Quigley NC, Reddi AH, Hollinger JO: Temporal changes during bone regeneration in the calvarium induced by osteogenin. Calcif Tissue Int 53:262-268, 1993
37. Marden LJ, Hollinger JO, Chaudhari A, Turek T, Schaub RG, Ron E: Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater Res 28:1127-1138, 1994
38. Habeeb A: Determination of free amino groups in proteins by trinitrobenezenesilfonic acid. Anal Biochem 14:328-336, 1966
39. Ling X, Sakashita N, Takeya M, Nagai R, Horiuchi S, Takahashi K: Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest 78:1591-1606, 1998
40. Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M: Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) 44:1147-1157, 1998
41. Bellows CG, Aubin JE, Heersche JN, Antosz ME: Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 38:143-154, 1986
42. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
43. Leiter EH, Prochazka M, Coleman DL: The non-obese diabetic (NOD) mouse. Am J Pathol 128:380-383, 1987
44. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N: Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 11:931-937, 1996
45. Katayama Y, Celic S, Nagata N, Martin TJ, Findlay DM: Nonenzymatic glycation of type I collagen modifies interaction with UMR 201-10B preosteoblastic cells. Bone 21:237-242, 1997
46. Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T: Advanced glycation endproducts stimulate Interleukin-6 production by human bone derived cells. J Bone Miner Res 12:439-446, 1997
47. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004, 1992
48. Goodman WG, Hori MT: Diminished bone formation in experimental diabetes: relationship to osteoid maturation and mineralization. Diabetes 33:825-831, 1984
49. Wu K, Schubeck KE, Frost HM, Villanueva A: Haversian bone formation rates determined by a new method in a mastodon, and in human diabetes mellitus and osteoporosis. Calcif Tissue Res 6:204-219, 1970
50. McCarthy AD, Etcheverry SB, Cortizo AM: Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol 36:45-52, 1999
51. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 89:12043-12047, 1992
52. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708, 1994
53. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S: Role of advanced glycation end products in a dynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38: S161-S164, 2001